natgillin/translations-raw huggingface dataset:
When activity, concentrations and protein binding are taken into account, pioglitazone and metabolite M-III contribute equally to efficacy.
Upoštevaje aktivnost, koncentracijo in vezavo na beljakovine k aktivnosti v enaki meri prispevata pioglitazon in presnovek M-III.
When added to metformin the dose of metformin should remain unchanged, however when combined with a sulphonylurea or insulin, a lower
Kadar se zdravilo dodaja metforminu, mora odmerek metformina ostati enak, pri kombinaciji s sulfonilsečnino ali insulinom pa je
When added to pioglitazone, the improvement was a fall of 0.47% at a dose of alogliptin of 12.5 mg, and 0.61% for alogliptin 25 mg.
Alogliptin, ki so ga dodajali pioglitazonu, je pri odmerku 12,5 mg znižal vrednosti za 0,47 %, pri odmerku 25 mg pa za 0,61 %.
When adding IT ziconotide to stable doses of IT morphine, as with the initiation of IT ziconotide monotherapy, the appearance of psychotic adverse reactions (e.g., hallucinations, paranoid reactions) or discontinuation due to increased adverse reactions may occur. (see section 4.5).
Kadar se IT zikonotid dodaja ustaljenim odmerkom IT morfina, kot ob začetku monoterapije z IT zikonotidom, lahko pride do pojava neželenih psihotičnih učinkov (npr. halucinacij, paranoidnih reakcij) ali do prekinitve zdravljenja zaradi povečanja neželenih učinkov (glejte poglavje 4.5).
When adding IT ziconotide to stable doses of IT morphine, as with the initiation of IT ziconotide monotherapy, the appearance of psychotic adverse reactions. (e.g., hallucinations, paranoid reactions) or discontinuation due to increased adverse reactions. may occur. (see section 4.5).
Kadar se IT zikonotid dodaja ustaljenim odmerkom IT morfina, kot ob začetku monoterapije z IT zikonotidom, lahko pride do pojava neželenih psihotičnih učinkov (npr. halucinacij, paranoidnih reakcij) ali do prekinitve zdravljenja zaradi povečanja neželenih učinkov (glejte poglavje 4.5).
When adding Tresiba to GLP-1 receptor agonists, the recommended daily starting dose is 10 units followed by individual dosage adjustments.
Pri dodajanju zdravila Tresiba k zdravljenju z agonistom receptorjev GLP-1 je priporočeni začetni dnevni odmerek zdravila Tresiba 10 enot, nato pa je treba odmerek prilagoditi vsakemu bolniku posebej.
When adjusted for body weight, steady state plasma exposure of valdecoxib was 16% higher in elderly females compared to elderly males (see section 4.2).
Po prilagoditvi za telesno težo je bila ravnotežna plazemska izpostavljenost valdekoksibu pri starejših ženskah 16 % večja kot pri starejših moških (glejte poglavje 4.2).
When adjusted for exposure, the adverse event rates were generally comparable with those observed during the initial study period.
Po prilagoditvi podatkov glede na trajanje izpostavljenosti so bile pogostnosti neželenih dogodkov približno enake kot v začetnem obdobju študije.
When adjusted on prognostic factors, the analyses of PFS in the subgroups of patients without or with prior cisplatin showed a HR (95% CI) = [0.51(0.31 – 0.86); p=0.0111] and a HR (95% CI) = [0.63(0.48 – 0.84); p=0.0016], respectively.
Po korekciji za prognostične dejavnike so analize preživetja brez napredovanja bolezni v podskupinah bolnikov s predhodnim cisplatinom in brez njega pokazale HR (95-odstotni IZ) = [0,51(0,31 – 0,86); p=0,0111] brez predhodnega cisplatina in HR (95-odstotni IZ) = [0,63(0,48 – 0,84); p=0,0016] po predhodno uporabljenem cisplatinu.
When administered 1 or 4 hours after 10 mcg lixisenatide, Cmax of paracetamol was decreased by 29% and 31% respectively and median tmax was delayed by 2.0 and 1.75 hours respectively.
Če je bil paracetamol uporabljen 1 uro po injiciranju 10 mcg liksisenatida, se je Cmax paracetamola znižala za 29 %, njegov mediani tmax pa se je podaljšal za 2,0 uri; če je bil uporabljen 4 ure po injiciranju, je bilo znižanje Cmax 31 % in podaljšanje tmax 1,75 ure.
When administered 1 or 4 hours after 10-mcg lixisenatide , Cmax of paracetamol was decreased by 29% and 31% respectively and median tmax was delayed by 2.0 and 1.75 hours respectively.
Če je bil paracetamol uporabljen 1 uro po injiciranju 10 mcg liksisenatida, se je Cmax paracetamola znižala za 29 %, njegov mediani tmax pa se je podaljšal za 2,0 uri; če je bil uporabljen 4 ure po injiciranju, je bilo znižanje Cmax 31 % in podaljšanje tmax 1,75 ure.
When administered by CSII no other medicinal products or other insulin products should be mixed in the reservoir of the infusion pump with Velosulin.
Kadar se Velosulin uporablja v stalni subkutani infuziji, se z njim v rezervoarju infuzijske crpalke ne sme mešati nobenih drugih zdravil ali drugih insulinov.
When administered concomitantly with lopinavir+ritonavir, or other ritonavir-boosted protease inhibitors, the patient’s tolerability of STAYVEER should be monitored.
Pri sočasnem dajanju lopinavirja in ritonavirja ali drugih zaviralcev proteaze, ki jih okrepi ritonavir, je treba nadzirati prenašanje zdravila STAYVEER pri bolniku.
When administered concomitantly with lopinavir+ritonavir, or other ritonavir-boosted protease inhibitors, the patient’s tolerability of Tracleer should be monitored.
Pri sočasnem dajanju lopinavirja in ritonavirja ali drugih zaviralcev proteaze, ki jih okrepi ritonavir, je treba nadzirati prenašanje zdravila Tracleer pri bolniku.
When administered concomitantly with nelfinavir, the patient’s tolerability of bosentan should be monitored.
Kadar se daje sočasno z nelfinavirjem, se mora spremljati prenašanje bosentana.
When administered concomitantly with PREZISTA and low dose ritonavir, the patient’s tolerability of bosentan should be monitored.
Ob sočasni uporabi z zdravilom PREZISTA in majhnim odmerkom ritonavirja je treba spremljati kako bolnik prenaša bosentan.
When administered concurrently, the following medicinal products may interact with thiazide diuretics:
Naslednja zdravila lahko pri sočasni uporabi medsebojno delujejo s tiazidnimi diuretiki:
When administered concurrently, the following medicinal products may interact with thiazide diuretics:
Ob sočasnem jemanju se lahko pojavijo interakcije med tiazidnimi diuretiki in naslednjimi v nadaljevanju navedenimi zdravili.
When administered concurrently, the following medicinal products may interact with thiazide diuretics:
Ob sočasni uporabi se lahko pojavijo interakcije med tiazidnimi diuretiki in naslednjimi zdravili:
When administered in combination, the CL of nivolumab increased by 25% in the presence of anti- nivolumab antibodies.
Pri kombinirani uporabi se je očistek nivolumaba v prisotnosti protiteles proti nivolumabu povečal za 25 %.
When administered in combination, the CL of nivolumab was increased by 35%, whereas there was no effect on the CL of ipilimumab.
Pri kombinirani uporabi se je očistek nivolumaba povečal za 35 %, vpliva na očistek ipilimumaba pa ni bilo.
When administered in combinationtherapy, patients with impaired renal function should be more carefully monitored with respect to the development of anaemia.
Pri kombinirani terapiji je treba bolnike z okvarjeno ledvično funkcijo bolj skrbno spremljati glede pojava anemije.
When administered in conjunction with a thrombolytic (fibrin specific or non-fibrin specific) enoxaparin sodium should be given between 15 minutes before and 30 minutes after the start of fibrinolytic therapy.
Pri sočasnem dajanju s trombolitikom (fibrinolitičnim ali nefibrinolitičnim) je treba natrijev enoksaparinat dati v obdobju od 15 minut pred začetkom fibrinolitične terapije do 30 minut po njem.
When administered in conjunction with a thrombolytic (fibrin specific or non-fibrin specific) enoxaparin sodium should be given between 15 minutes before and 30 minutes after the start of fibrinolytic therapy.
Pri sočasnem dajanju s trombolitikom (fibrinolitičnim ali nefibrinolitičnim) je treba natrijev enoksaparinat dati v obdobju od 15 minut pred začetkom fibrinolitične terapije in do 30 minut po njem.
When administered in hypertensive patients with markedly elevated blood pressure (systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg), Riprazo HCT in doses from 150 mg/12.5 mg to 300 mg/25 mg administered without up-titration from monotherapy demonstrated significantly greater systolic/diastolic blood pressure control rates (< 140/90 mmHg) as compared to the respective monotherapies.
150 mg/12,5 mg do 300 mg/25 mg pri statistično značilno večjem deležu bolnikov uravnalo sistolični/diastolični krvni tlak (< 140/90 mmHg) v primerjavi z uporabo posameznih monoterapij.
When administered in the PCI setting, cangrelor was associated with a greater incidence of GUSTO mild bleeding compared with clopidogrel.
Pri dajanju v povezavi s PCI je bil kangrelor povezan z večjo incidenco blagih krvavitev po lestvici GUSTO v primerjavi s klopidogrelom.
When administered subcutaneously care should be taken when injecting Humalog BASAL to ensure that a blood vessel has not been entered.
Pri subkutanem injiciranju zdravila Humalog BASAL je potrebna previdnost, da zdravila ne vbrizgamo v žilo.
When administered subcutaneously care should be taken when injecting Humalog KwikPen to ensure that a blood vessel has not been entered.
Pri subkutanem injiciranju zdravila Humalog KwikPen je potrebna previdnost, da zdravila ne vbrizgamo v žilo.
When administered subcutaneously care should be taken when injecting Liprolog Basal to ensure that a blood vessel has not been entered.
Pri subkutanem injiciranju zdravila Liprolog Basal je potrebna previdnost, da zdravila ne vbrizgamo v žilo.
When administered subcutaneously care should be taken when injecting Liprolog KwikPen to ensure that a blood vessel has not been entered.
Pri subkutanem injiciranju zdravila Liprolog KwikPen je potrebna previdnost, da zdravila ne vbrizgamo v žilo.
When administered subcutaneously, care should be taken when injecting Humalog Mix50 to ensure that a blood vessel has not been entered.
Pri subkutanem injiciranju zdravila Humalog Mix50 je potrebna previdnost, da zdravila ne vbrizgamo v žilo.
When administered through a Y-site, compatibility of tigecycline diluted in sodium chloride 0.9 % for injection is demonstrated with the following medicinal products or diluents: amikacin, dobutamine, dopamine HCl, gentamicin, haloperidol, Lactated Ringer’s, lidocaine HCl, metoclopramide, morphine, norepinephrine, piperacillin/tazobactam (EDTA formulation), potassium chloride, propofol, ranitidine HCl, theophylline, and tobramycin.
Kompatibilnost tigeciklina, razredčenega z 0,9-odstotnim natrijevim kloridom za injiciranje, pri injiciranju v podaljšek Y so dokazali za naslednja zdravila in vehikle: amikacin, dobutamin, dopaminijev hidroklorid, gentamicin, haloperidol, Ringerjev laktat, lidokainijev hidroklorid, metoklopramid, morfin, noradrenalin, piperacilin/tazobaktam (pripravek z EDTA), kalijev klorid, propofol, ranitidinijev hidroklorid, teofilin in tobramicin.
When administered to older pigs (14–23 weeks of age) injection site swellings ranging from 2 cm to 5 cm in diameter are commonly observed, and injection site reactions at slaughter are commonly observed if the second vaccination is given only 4 weeks before slaughter.
Pri dajanju starejšim prašičem (14-23 tednov starosti) so na mestu injiciranja pogosto opazne otekline razpona od 2 do 5 cm v premeru, če pa je bilo drugo cepljenje izvedeno samo 4 tedne pred klanjem, so pri zakolu pogosto opazne tudi reakcije na mestu injiciranja.
When administered to pigs at the youngest recommended age (8 weeks), injection site swellings of up to 4 x 8 cm are very commonly observed.
Pri dajanju prašičem pri najnižji priporočeni starosti (8 tednov), so bile na mestu dajanja zelo pogosto opazne otekline do 4x8 cm.
When administered twice daily (b.i.d.), in case a dose of INCIVO is missed within 6 hours of the time it is usually taken, patients should be instructed to take the prescribed dose of INCIVO with food as soon as possible.
Jemanje zdravila dvakrat na dan: v primeru, da bolnik pozabi vzeti odmerek zdravila INCIVO do 6 ur po času, ko ga običajno jemlje, mu naročite, naj čimprej vzame predpisani odmerek zdravila INCIVO s hrano.
when administered with
1,10 (0,97-1,26)
when administered with
potrebna, kadar se
when administered with
Pri režimih, kjer
When administered with atorvastatin the dose of Lojuxta should either be taken 12 hours apart or be decreased by half (see section 4.2).
Pri dajanju z atorvastatinom je treba odmerek zdravila Lojuxta zamakniti za 12 ur ali zmanjšati za polovico (glejte poglavje 4.2).
When administered with atorvastatin, the dose of Lojuxta should either be taken 12 hours apart or be decreased by half (see section 4.2).
Pri dajanju z atorvastatinom je treba odmerek zdravila Lojuxta zamakniti za 12 ur ali zmanjšati za polovico (glejte poglavje 4.2).
When administered with Perjeta the recommended initial dose of docetaxel is 75 mg/m2, administered thereafter on a 3 weekly schedule.
Priporočen začetni odmerek docetaksela ob zdravilu Perjeta je 75 mg/m2, ki mu sledi vzdrževalni odmerek vsake 3 tedne.
When administered with Perjeta the recommended initial loading dose of trastuzumab is 8 mg/kg body weight administered as an intravenous infusion followed every 3 weeks thereafter by a maintenance dose of 6 mg/kg body weight.
Priporočeni začetni uvajalni odmerek trastuzumaba ob zdravilu Perjeta je 8 mg/kg telesne mase v intravenski infuziji, ki mu sledi vzdrževalni odmerek trastuzumaba 6 mg/kg telesne mase vsake 3 tedne.
When administering any medicinal product where a reduction in the bioavailability could have a clinically significant effect on safety or efficacy, the medicinal product should be administered at least one hour before or three hours after Renagel, or the physician should consider monitoring blood levels.
Pri dajanju katerih koli zdravil, pri katerih ima lahko zmanjšana biološka uporabnost klinično značilen vpliv na varnost ali učinkovitost, je treba zdravilo dati vsaj eno uro pred ali tri ure po uporabi zdravila Renagel, ali pa mora zdravnik razmisliti o nadzoru ravni v krvi.
When administering any medicinal product where a reduction in the bioavailability could have a clinically significant effect on safety or efficacy, the medicinal product should be administered at least one hour before or three hours after Renvela, or the physician should consider monitoring blood levels.
Pri dajanju katerih koli zdravil, pri katerih ima lahko zmanjšanja biološka uporabnost klinično značilen vpliv na varnost ali učinkovitost, je treba zdravilo uporabiti vsaj eno uro pred ali tri ure po uporabi zdravila Renvela, ali pa mora zdravnik razmisliti o nadzoru ravni v krvi.
When administering any medicinal product where a reduction in the bioavailability could have a clinically significant effect on safety or efficacy, the medicinal product should be administered at least one hour before or three hours after Sevelamer carbonate Zentiva, or the physician should consider monitoring blood levels.
Pri dajanju katerih koli zdravil, pri katerih ima lahko zmanjšanja biološka uporabnost klinično značilen vpliv na varnost ali učinkovitost, je treba zdravilo uporabiti vsaj eno uro pred ali tri ure po uporabi zdravila Sevelamer carbonate Zentiva, ali pa mora zdravnik razmisliti o nadzoru ravni v krvi.
When administering drotrecogin alfa (activated) at low flow rates (less than approximately 5 ml/hr), the infusion set must be primed for approximately 15 minutes at a flow rate of approximately 5 ml/hr.
Pri dajanju drotrekogina alfa (aktiviranega) pri nizkih hitrostih pretoka (manj kot približno 5 ml/h) je treba infuzijski sistem pripravljati približno 15 minut s hitrostjo pretoka približno 5 ml/h.
When administering drotrecogin alfa (activated) at low flow rates (less than approximately 5 ml/hr), the infusion set must be primed for approximately 15 minutes at a flow rate of approximately 5 ml/hr.
Pri dajanju drotrekogina alfa (aktiviranega) pri nizkih hitrostih pretoka (manj kot približno 5 ml/h) morate infuzijski sistem pripravljati približno 15 minut s hitrostjo pretoka približno 5 ml/h.
When administering in an intravenous bag, withdraw the calculated dose from the vial and dilute into a 50 or 100 mL intravenous bag containing 5% glucose solution for injection.
V primeru uporabe v intravenski vrečki izvlecite izračunani odmerek iz viale in ga razredčite v 50 ali 100 ml intravenski vrečki, ki vsebuje 5 % raztopino glukoze za injiciranje.
When administering in an intravenous bag, withdraw the calculated dose from the vial and dilute into a 50 or 100 mL intravenous bag containing 5% glucose solution for injection.
V primeru uporabe v intravenski vrečki povlecite izračunani odmerek iz viale in ga razredčite v 50 ali 100 ml intravenski vrečki, ki vsebuje 5 % raztopino glukoze za injiciranje.
When administering Jakavi with strong CYP3A4 inhibitors the unit dose of Jakavi should be reduced by approximately 50%, to be administered twice daily.
Pri sočasnem odmerjanju zdravila Jakavi z močnimi zaviralci CYP3A4, je treba posamezen odmerek zdravila Jakavi znižati za približno 50 % in ga odmerjati dvakrat na dan.
When administering the veterinary medicinal product, take care to avoid accidental self-injection by ensuring that animals are suitably restrained and the application needle is shielded until the moment of implantation.
Pri dajanju veterinarskega zdravila pazite, da bodo živali primerno imobilizirane in da bo igla za dajanje zdravila zaščitena s pokrovčkom vse do trenutka implantacije, da si zdravila ne bi nehote samoinjicirali.
When administering the veterinary medicinal product, take care to avoid accidental self-injection by ensuring that animals are suitably restrained and the application needle is shielded until the moment of implantation.
Pri dajanju zdravila pazite, da bodo živali primerno imobilizirane in da bo igla za dajanje zdravila zaščitena s pokrovčkom vse do trenutka implantacije, da si zdravila ne bi nehote samoinjicirali.
When administering two injections in the same hand during a treatment visit, use a new syringe and separate vial of reconstituted solution (containing 0.58 mg of Xiapex) for the second injection.
Pri dajanju dveh injekcij v isto roko med obiskom za zdravljenje je treba uporabiti novo injekcijsko brizgo in ločeno vialo z rekonstituirano raztopino (ki vsebuje 0,58 mg zdravila Xiapex) za drugo injekcijo.
When administering with Tybost, the maximum daily dose of itraconazole should not exceed 200 mg per day.
Pri dajanju z zdravilom Tybost največji dnevni odmerek itrakonazola ne sme preseči 200 mg dnevno.
When administration is by injection reconstitute with 0.9% sodium chloride only.
Za vnos z injiciranjem pripravite zdravilo samo z 0,9-odstotno raztopino natrijevega klorida.
When administration of atorvastatin and boosted PREZISTA is desired, it is recommended to start with an atorvastatin dose of 10 mg once daily.
Če želite uporabljati atorvastatin in okrepljeno zdravilo PREZISTA, je priporočljivo začeti z odmerkom atorvastatina 10 mg enkrat na dan.
When administration of atorvastatin and PREZISTA co-administered with low dose ritonavir is desired, it is recommended to start with an atorvastatin dose of 10 mg once daily.
Če želite uporabljati atorvastatin in zdravilo PREZISTA z majhnim odmerkom ritonavirja, je priporočljivo začeti z odmerkom atorvastatina 10 mg enkrat na dan.
When administration of pravastatin
Če je potrebna sočasna uporaba
When Akynzeo is used concomitantly with another CYP3A4 inhibitor, netupitant plasma concentrations could be elevated.
Ob sočasni uporabi zdravila Akynzeo z drugim zaviralcem CYP3A4 lahko pride do zvišanja plazemskih koncentracij netupitanta.
When Akynzeo is used concomitantly with medicinal products that induce CYP3A4 activity, netupitant plasma concentrations could be reduced and this may result in decreased efficacy.
Pri sočasni uporabi zdravila Akynzeo in zdravil, ki spodbujajo delovanje CYP3A4, lahko pride do znižanja plazemskih koncentracij netupitanta, kar lahko privede do zmanjšane učinkovitosti.
When all of the medicine has been delivered, you will hear two ‘beeps’, which means the treatment is complete.
Ko je dostavljeno vse zdravilo, boste slišali dva piska, kar pomeni, da je zdravljenje končano.
When allopurinol and Xaluprine are administered concomitantly it is essential that only a quarter of the usual dose of Xaluprine is given since allopurinol decreases the rate of metabolism of 6– mercaptopurine via xanthine oxidase.
Pri sočasni uporabi alopurinola in zdravila Xaluprine je zelo pomembno, da se uporablja le četrtina siceršnjega odmerka zdravila Xaluprine, saj alopurinol zmanjšuje hitrost presnavljanja 6- merkaptopurina prek ksantin-oksidaze.
When Ambirix was administered concomitantly with, but as a separate injection to a combined diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b vaccine (DTPa-IPV+Hib) or with a combined Measles-Mumps-Rubella vaccine in the second year of life, immune responses to all antigens were satisfactory (see section 5.1).
Pri sočasnem vendar ločenem injiciranju cepiva Ambirix in mešanega cepiva proti davici, tetanusu, oslovskemu kašlju – acelularno, otroški ohromelosti – inaktivirano in Haemophilusu influenzae tipa b (DTPa-IPV+Hib) ali mešanega cepiva proti ošpicam, mumpsu in rdečkam v drugem letu življenja, je bil imunski odziv na vse antigene zadovoljiv (glejte poglavje 5.1).
When an administration of radiopharmaceuticals to a woman of childbearing potential is intended, it is important to determine whether or not she is pregnant.
Kadar je indicirana uporaba radiofarmakov pri ženski v rodni dobi, je pomembno, da se prepričate ali je noseča ali ne.
When an attack occurred, the patients were given one of two doses of Ruconest (50 or 100 units/kg) or placebo (a dummy treatment).
Ob napadu so bolniki prejeli enega od dveh odmerkov zdravila Ruconest (50 ali 100 enot/kg) ali placeba (zdravila brez zdravilne učinkovine).
When an individual is vaccinated with Gardasil 9, the immune system (the body’s natural defence system) stimulates production of antibodies against the nine vaccine HPV types, to help protect against the diseases caused by these viruses.
Cepljenje s cepivom Gardasil 9 povzroči, da imunski sistem (naravna obramba telesa) spodbudi nastajanje protiteles proti devetim tipom HPV v cepivu, kar pomaga ščititi pred boleznimi, ki jih povzročajo ti virusi.
When an individual’s adverse reactions are under effective management, dose re-escalation following the same dosing steps as de-escalation may be considered.
Ko so neželeni učinki učinkovito obvladani, pride v poštev ponovno zvišanje odmerka.
When an individual’s adverse reactions are under effective management, dose re-escalation following the same dosing steps as de-escalation may be considered.
Ko so neželeni učinki učinkovito obvladani, pride v poštev ponovno zvišanje odmerka; pri tem je treba zvišanje opraviti po enakih stopnjah, kot je bilo opravljeno znižanje.
When an infant is given the vaccine, the immune system (the body’s natural defences) will make antibodies against the most commonly occurring types of rotavirus.
Ko dojenček prejme cepivo, imunski sistem (naravna obramba telesa) proizvede protitelesa proti najpogostejšim tipom rotavirusov.
When an infant is given the vaccine, the immune system (the system that fights diseases) recognises the weakened virus as ‘foreign’ and makes defences against it.
Ko dojenček prejme cepivo, imunski sistem (sistem, ki se bori proti boleznim) prepozna oslabljeni virus kot „tujek“ in proti njemu začne tvoriti protitelesa.
When an infant is given the vaccine, the immune system recognises the parts of the bacteria and viruses as ‘foreign’ and makes antibodies against them.
Ko dojenček prejme cepivo, imunski sistem prepozna dele bakterij in virusov kot „tujke“ in proti njim razvije protitelesa.
When an infant is given the vaccine, the immune system recognises the parts of the bacteria and viruses as ‘foreign’ and makes antibodies against them.
Ko otrok prejme cepivo, imunski sistem prepozna dele bakterij in virusov kot „tujke“ in proti njim razvije protitelesa.
When an infant is given the vaccine, the immune system recognises the parts of the bacteria and viruses as ‘foreign’ and makes antibodies against them.
Ko otroka cepimo, imunski sistem prepozna dele bakterij in virusa kot „tuje“ in izdela protitelesa, usmerjena proti njim.